aiSwingX™ analyzes US filings and reports them as news investors can read.

–

ChatGPT: 0 Claude: 0 Google · Gemini: 0 Perplexity: 0 Meta AI: 0 Amazon: 0 Others: 2

Read by AI & crawlers

ChatGPT0

Claude0

Google · Gemini0

Perplexity0

Meta AI0

Amazon0

Others2

Counted by the name each crawler gives. Google · Gemini includes Googlebot, whose index Google also uses for its AI features; other search engines and bots are in Others.

Filing fact · MDGL · 10-Q · 2026-11-03

Revenue

MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Revenue of USD 431,268,000 for the period from 2026-07-01 to 2026-09-30 in its 10-Q (accession 0001628280-26-069145, filed 2026-11-03).

Period	Value	Verify
2026-07-01 ~ 2026-09-30	$431,268,000	EDGAR ↗
2025-09-30 (comparative)	$287,268,000	EDGAR ↗

Our analysis of this filing → EDGAR filing index ↗ MDGL overview →

Provenance

Company MADRIGAL PHARMACEUTICALS, INC. · CIK 1157601
Form 10-Q · Accession 0001628280-26-069145 · Filed 2026-11-03
XBRL tag us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · unit USD · duration

Values are read directly from the inline XBRL the company filed with EDGAR. The EDGAR links above point to the exact figure inside the filing document. No ratios or interpretation are added here.

Cite this

MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Revenue of USD 431,268,000 for the period from 2026-07-01 to 2026-09-30 in its 10-Q (accession 0001628280-26-069145, filed 2026-11-03).
— aiSwingX, https://aiswingx.com/n/0001628280-26-069145/RevenueFromContractWithCustomerExcludingAssessedTax

JSON: /api/v1/facts/0001628280-26-069145/RevenueFromContractWithCustomerExcludingAssessedTax